Renin–angiotensin system blockade alone or combined with ET_A receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats

References

• U.S. Renal Data System: USRDS. Annual Data Report 2015. Epidemiology of kidney disease in the United States.
   Google Scholar
• Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013;382:260–272.
   PubMed Web of Science ®Google Scholar
• Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985;249:F324–F337.
   PubMed Web of Science ®Google Scholar
• Zoja C, Abbate M, Remuzzi G. Progression of chronic kidney disease: insight from animal models. Curr Opin Nephrol Hypertens 2006;15:250–257.
   PubMed Web of Science ®Google Scholar
• Shimamura T, Morrison AB. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 1975;79:95–106.
   PubMed Web of Science ®Google Scholar
• Carlström M, Wilcox CS, Arendshorst WJ. Renal autoregulation in health and disease Physiol Rev 2015;95:405–511.
   PubMed Web of Science ®Google Scholar
• Kobori H. Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251–287.
   Google Scholar
• Kujal P, Certíková Chábová V, Vernerová Z, et al. Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects? Clin Exp Pharmacol Physiol 2010;37:1159–1169.
   PubMed Web of Science ®Google Scholar
• Turner JM, Bauer C, Abramowitz MK, et al. Treatment of chronic kidney disease. Kidney Int 2012;81:351–362.
   PubMed Web of Science ®Google Scholar
• Ripley E. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in slowing the progression of chronic kidney disease. Am Heart J 2009;157:S7–S16.
   PubMed Web of Science ®Google Scholar
• Remuzzi A, Sangalli F, Macconi D, et al. Regression of renal disease by angiotensin II antagonism is caused by regeneration of kidney vasculature. J Am Soc Nephrol 2016;27:699–705.
   PubMed Web of Science ®Google Scholar
• Berl T. Renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2009;10:1–8.
   PubMed Web of Science ®Google Scholar
• Breyer MD, Susztak K. The next generation of therapeutics for chronic kidney disease. Nat Rev Drug Discov 2016.
   PubMed Web of Science ®Google Scholar
• Czopek A, Moorhouse R, Webb DJ, Dhaun N. Therapeutic potential of endothelin receptor antagonism in kidney disease. Am J Physiol 2016;310:R388–R397.
   Google Scholar
• Komers R, Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol 2016;310:R877–R884.
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–415.
   PubMed Web of Science ®Google Scholar
• Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev 2016;68:357–418.
   PubMed Web of Science ®Google Scholar
• Lariviére R, D´Amours M, Lebel M, et al. Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal mass. Kidney Blood Press Res 1997;20:372–380.
   PubMed Web of Science ®Google Scholar
• Vaněčková I, Kramer H, Backer A, et al. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension 2005;46:969–974.
   PubMed Web of Science ®Google Scholar
• Sasser JM, Pollock JS, Pollock DM. Renal endothelin in chronic angiotensin II hypertension. Am J Physiol 2002;283:R243–R248.
   Google Scholar
• Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and renin-angiotensin-aldosterone system. Cardiovasc Res 1999;43:300–307.
   PubMed Web of Science ®Google Scholar
• De Miquel C, Speed JS, Kasztan M, et al. Endothelin-1 and the kidney: new perspectives and recent findings. Curr Opin Nephrol Hypertens 2016;25:35–41.
   PubMed Web of Science ®Google Scholar
• Vaněčková I, Kujal P, Husková Z, et al. Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats. Kidney Blood Press Res 2012;35:382–392.
   PubMed Web of Science ®Google Scholar
• Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990;344 541–544.
   PubMed Web of Science ®Google Scholar
• Čertíková Chábová V, Vernerová Z, Kujal P, et al. Addition of ETA receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats. Life Sci 2014;118:297–305.
   PubMed Web of Science ®Google Scholar
• Fujihara CK, Velho M, Malheiros DM, Zatz R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 2005;67:1913–1924.
   PubMed Web of Science ®Google Scholar
• Husková Z, Kopkan L, Červenková L, et al. Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1–7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol 2016;43:438–449.
   PubMed Web of Science ®Google Scholar
• Huskova Z, Kramer HJ, Thumova M, et al. Effects of anesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Kidney Blood Press Res 2006;29:74–83.
   PubMed Web of Science ®Google Scholar
• Červenka L, Bíbová J, Husková Z, et al. Combined suppression of the intrarenal and circulating renin-ACE-ANG II axis and augmentation of the vasodilator ACE2-ANG 1-7-Mas axis attenuates the systemic hypertension in Ren-2 transgenic rats exposed to chronic hypoxia. Physiol Res 2015;64:11–24.
   PubMed Web of Science ®Google Scholar
• Vaňourková Z, Kramer HJ, Erbanová M, et al. Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in Cyp1a1-Ren-2 transgenic rats with acutely induced hypertension. Vascul Pharmacol 2009;50:194–199.
   PubMed Web of Science ®Google Scholar
• Cervenka L, Wang CT, Navar LG. Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats. Am J Physiol 1998;274:F940–F945.
   PubMed Web of Science ®Google Scholar
• Cervenka L, Wang CT, Mitchell KD, Navar LG. Proximal tubular angiotensin II levels and renal functional responses to AT1 receptor blockade in nonclipped kidneys of Goldblatt hypertensive rats. Hypertension 1999;33:102–107.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK, et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest 2013;125:2011–2023.
   Web of Science ®Google Scholar
• Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol 2016;310:H137–H152.
   PubMed Web of Science ®Google Scholar
• Barton M, Shaw S, d´Uscio LV, et al. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin-converting enzyme activity in vivo: role of ET_A receptors for endothelin regulation. Biochem Biophys Res Commun 1997;238:861–865.
   Google Scholar
• Vaněčková I, Dobešová Z, Kuneš J, et al. Endothelin A receptor blocker atrasentan lowers blood pressure by the reduction of nifedipine-sensitive calcium influx in Ren-2 transgenic rats fed a high-salt diet. J Hypertens 2015;33:161–169.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes vs. Hypertrophy in experimental glomerular sclerosis. Kidney Int 1989;35:654–660.
   PubMed Web of Science ®Google Scholar
• Carmines PK, Perry MD, Hazelrig JB, Navar LG. Effects of preglomerular and postglomerular vascular resistance alterations on filtration fraction. Kidney Int. Suppl 1987;20:S229–S232.
   Google Scholar
• Sumners C, de Kloet AD, Krause EG, et al. Angiotensin type 2 receptors: blood pressure regulation and end organ damage. Curr Opin Pharmacol 2015;21:115–121.
   PubMed Web of Science ®Google Scholar
• Saleh MA, Sandoval RM, Rhodes GJ, et al. Chronic endothelin-1 infusion elevates glomerular sieving coefficient and proximal tubular albumin reuptake in the rat. Life Sci 2012;91:624637.
   Web of Science ®Google Scholar
• Rossi GP. Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists? Curr Hypertens Rep 2006;8:262–268.
   PubMed Web of Science ®Google Scholar
• Piuhola J, Makinen M, Szokodi I, Ruskoaho H. Dual role of endothelin-1 via ETA and ETB receptors in regulation of cardiac contractile function in mice. Am J Physiol 2003;285:H112–H118.
   Google Scholar
• Taal M, Brenner B. Combination ACEI and ARB therapy: additional benefit in renoprotection. Curr Opin Nephrol Hypertens 2002;11:377–381.
   PubMed Web of Science ®Google Scholar
• Bakris GL. Dual RAAS blockade is desirable in kidney disease: Con Kidney Int 2010;78:546–549.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Tylicky L, Renke M, et al. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis 2004;43:260–268.
   PubMed Web of Science ®Google Scholar
• The ONTARGET Investigators. Telmisartan, remipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–1559.
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, et al. Pfeffer MA for the ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204–2213.
   Google Scholar
• Fried LF, Emanuele N, Zhang JH, et al. for the VA NEPHRON-D Investigators. N Engl J Med 2013;369:1892–1903.
   PubMed Web of Science ®Google Scholar
• Miao Y, Dobre D, Heerspink HJ, et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the reductions of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial. Diabetologia 2011;54:44–50.
   PubMed Web of Science ®Google Scholar
• Rutkowski B, Tylicki L. Nephroprotective action of renin-angiotesin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trials. J Ren Nutr 2015;25:194–200.
   PubMed Web of Science ®Google Scholar
• Study of diabetic nephropathy with Atresantan (SONAR). ClinicalTrials.gov no. NCT01858532 (http://clinicaltrilas.gov/ct2/show/NCT01858532).
   Google Scholar
• Mann JF, Green D, Jamerson K, et al., ASCEND Study Group. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527–535.
   PubMed Web of Science ®Google Scholar
• De Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atresantan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 2014;25:1083–1093.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Lambers Heerspink HJ, Coll B, et al. Predictors of atrasentan-associated fluid retention and change in albuminuria in patients with diabetic nephropathy. Clin J Am Soc Nephrol 2015;10:1568–1574.
   PubMed Web of Science ®Google Scholar